MRRS adds "Frontier Pharma: Schizophrenia and Associated Indications – Small but Diverse Range of First-in-Class Molecular Targets Hold Promise for Treatment of Negative and Cognitive Symptoms" latest studies, published in November 2016. It is a professional and in-depth study.

Summary
Schizophrenia is a severe mental disorder that is characterized by abnormal social behavior and failure to recognize what is real; its symptoms are broadly divided into positive, negative and cognitive. The treatment of schizophrenia is multi-factorial and includes medical, psychological and psychosocial inputs. Antipsychotic medication is the main pharmacological agent used, along with counselling, job training, and social rehabilitation. Both typical and atypical antipsychotics are used, and the choice of medication is usually left to the discretion of the treating physician. Clozapine, which is an atypical antipsychotic that binds to serotonin and dopamine receptors, is often given to patients who do not improve with other antipsychotics.

Current treatments, although effective for positive symptoms, have not proven as effective for negative symptoms and cognitive dysfunction, nor are there are any disease-modifying drugs currently available. The pipeline for schizophrenia is small, particularly given the large patient population, it also has low levels of innovation in comparison to other psychiatric indications in the pharmaceutical industry. However, the overall level of innovation in the pipeline for schizophrenia-related indications (which includes depression, panic disorders, obsessive compulsive disorder, post-traumatic stress disorder and cognitive deficit) is far higher, with these related products having the potential to provide some benefit to patients with schizophrenia.

Table of Contents
1 Table of Contents 2
2 Executive Summary 5
2.1 A Complex and Poorly Understood Disorder, with Numerous Unmet Needs 5
2.2 Small Pipeline for Schizophrenia with Few Signs of Innovation 5
2.3 Extensive Pipeline for Associated Indications 5
3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 GBI Research Report Guidance 8
4 Clinical and Commercial Landscape 9
4.1 Disease Overview 9
4.2 Epidemiology 9
4.3 Disease Etiology 9
4.4 Disease Pathophysiology 10
4.4.1 Susceptibility Genes 10
4.4.2 Neurotransmission Alterations 11
4.4.3 Phosphatidylinositol Signaling 11
4.5 Disease Symptoms 11
4.6 Indications Associated With Schizophrenia 11
4.6.1 Panic Disorder 11
4.6.2 Depression 12
4.6.3 Post-Traumatic Stress Disorder 13
4.6.4 Obsessive Compulsive Disorder 13
4.6.5 Cognitive Impairment 13
4.7 Diagnosis 14
4.8 Prognosis 15
4.9 Treatment Options 15
4.10 Overview of Marketed Products 16
4.10.1 Molecule Type and Target Analysis 16
4.11 Current Unmet Needs 17
5 Assessment of Pipeline Product Innovation 18......

List of Tables and Figures 
Table 1: American Psychiatry Association DSM-5 Schizophrenia Criteria 14
Table 2: World Health Organization ICD-10 Schizophrenia criteria 15
Table 3: Data for D-Amino Acid Oxidase as a Therapeutic Target 37
Table 4: Evidence for D-Amino Acid Oxidase as a Therapeutic Target 37
Table 5: Data for Gamma-Aminobutyric Acid Receptor, Subunit Alpha 5 as a Therapeutic Target 38
Table 6: Evidence for Gamma-Aminobutyric Acid Receptor, Subunit Alpha 5 as a Therapeutic Target 39
Table 7: Data for Glutamate Carboxypeptidase 2 as a Therapeutic Target 40
Table 8: Evidence for Glutamate Carboxypeptidase 2 as a Therapeutic Target 41
Table 9: Data for Phosphodiesterase 9 as a Therapeutic Target 42
Table 10: Evidence for Phosphodiesterase 9 as a Therapeutic Target 42
Table 11: Data for Potassium Voltage-Gated Channel Subfamily C, Member 1 as a Therapeutic Target 43
Table 12: Evidence for Potassium Voltage-Gated Channel Subfamily C, Member 1 as a Therapeutic Target 44
Table 13: Data for Probable G Protein-Coupled Receptor 52 as a Therapeutic Target 45.....

Browse Complete Report with TOC @
http://www.marketresearchreportstore.com/shop/frontier-pharma-schizophrenia-and-associated-indications-small-but-diverse-range-of-first-in-class-molecular-targets-hold-promise-for-treatment-of-negative-and-cognitive-symptoms

About Market Research Report Store
Since the establishment, Market Research Report Store has determined to take the online market research reports platform to the next level. With our passion and profession, we are designed to be the best among the bests.
Market Research Report Store is one of the most fast-growing and professional online platforms for industry reports, market reports, and professional surveys. Our collection covers more than 100 global markets. We have cooperated with leading publishers and consultant companies to offer the best market intelligence products to our clients with instant access to our database.

Ask a sample and any further questions, please feel free to contact us:
Tel: +00-1-626-3463946 - U.S
Email: [email protected]
Web: http://www.marketresearchreportstore.com/